AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca is conducting a Phase I/IIa study titled A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. The study aims to assess the safety, tolerability, and efficacy of AZD7789 in treating advanced solid tumors, a significant step in cancer treatment innovation.
Intervention/Treatment: The study tests AZD7789, a bispecific antibody targeting PD-1 and TIM-3, designed to enhance immune response against tumors.
Study Design: This interventional study is randomized and open-label, with a sequential intervention model. It includes two parts: dose escalation and dose expansion, focusing on treatment as the primary purpose.
Study Timeline: The study began on September 28, 2021, with the last update submitted on July 7, 2025. These dates are crucial for tracking the study’s progress and future updates.
Market Implications: This study could significantly impact AstraZeneca’s stock performance by potentially expanding its oncology portfolio. Success in this trial may enhance investor confidence and position AstraZeneca competitively in the cancer treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.